IVA Share Price Performance
€4.72
2.14 (82.95%)
47.4% undervalued intrinsic discount
€8.98
Fair Value
Price €4.72
AnalystConsensusTarget €8.98
AnalystHighTarget €11.40
Fair Value€8.98
Share Pricen/a
Inventiva S.A. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
IVA Community Narratives
AN
Fair Value €8.98 47.4% undervalued intrinsic discount
Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value €11.4 58.6% undervalued intrinsic discount
Global Aging Trends Will Spark Demand For MASH Treatments
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Global Aging Trends Will Spark Demand For MASH Treatments
Key Takeaways Leadership in multimodal metabolic therapies and innovative clinical positioning could drive outsized revenue and expand Inventiva's market reach over time. Decisive restructuring and strategic partnerships enhance margins and acquisition appeal, positioning the company for industry-leading financial performance and transformative growth opportunities.Read more
18
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
€11.4
58.6% undervalued intrinsic discount
Fair Value
Profit Margin
35.4%
Future PE
13.54x
Price in 2029
€13.81
Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress
Key Takeaways Strategic focus on lanifibranor development, cutting other activities, and reducing workforce may improve net margins through operational efficiency. Key partnerships in Asia and financial strength ensure market penetration and support sustained investment, boosting future earnings potential.Read more
198
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
€8.98
47.4% undervalued intrinsic discount
Fair Value
Profit Margin
35.4%
Future PE
32.47x
Price in 2029
€10.87
Trending Discussion
Recently Updated Narratives
AN
IVA: Bullish MASH Program Coverage Will Highlight Upcoming Clinical Milestone Catalysts
Fair Value: €11.4 58.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IVA: 2026 MASH Phase 3 Readout Expected To Drive Bullish Repricing
Fair Value: €8.98 47.4% undervalued intrinsic discount
10 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Inventiva S.A. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Sep 25, 2026
- -1.85
- 100.00%
- -4,468.05%
- -1,445.4%
About IVA
- Founded
- 2011
- Employees
- 84
- CEO
- WebsiteView website
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
